Caprie trial

There were first events included in the outcome cluster on which an intention-to-treat analysis showed that patients treated with clopidogrel had an annual 5. Clopidogrel prevented 21 more events per diabetic patients treated than did ASA. Clopidogrel and its precursor ticlopidine are thienopyridines. The results in the CURE study were compared in patients who did and did not have a coronary intervention procedure, in patients with different levels of risk based on the Thrombolysis in Myocardial Infarction score and in patients with and without a history of a revascularization procedure. Clopidogrel therapy resulted in a relative risk reduction of 8.

Uploader: Gonris
Date Added: 4 October 2017
File Size: 16.89 Mb
Operating Systems: Windows NT/2000/XP/2003/2003/7/8/10 MacOS 10/X
Downloads: 54071
Price: Free* [*Free Regsitration Required]





There is no potential for profit. A review of theCAPRIE database identified the following 5 clinically defined high-risk groups in whom an amplified absolute and relative risk trail is seen with clopidogrel treatment: On the other hand, the CAPRA study 13 suggests that in the real world, patients with atherothrombosis are at much higher risk compared with those enrolled in clinical trials such as CAPRIE and therefore more likely to derive benefit from effective therapies.

Sign in ccaprie customize your interests Sign in to your personal account. Purchase access Subscribe now. National Center for Biotechnology InformationU.

Sign in to save your search Sign in to your personal account. Long-term administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of ischaemic stroke, myocardial infarction, or vascular death. The CAPRIE csprie was conducted to evaluate the relative efficacy and safety of clopidogrel compared with ASA in reducing the risk of occurrence of the composite primary outcome cluster of ischemic stroke ISMI, or vascular death VDin patients at risk of ischemic events.

The results of these trials are important from 2 viewpoints. Of importance, all subgroups were at least as responsive to the beneficial effects of clopidogrel, either used alone or in combination with ASA, as the study population as caprue whole, and some of the identified high-risk groups assigned to clopidogrel showed a greater RRR compared with the population as a whole, suggesting the possibility that these subgroups might be more responsive to the antiplatelet effects of clopidogrel than to ASA.

CAPRIE - Wiki Journal Club

The results in the CURE study were compared in patients who did and did not have a coronary intervention procedure, in patients with different levels of risk based on the Thrombolysis in Myocardial Infarction score and in patients with and without a history of a revascularization procedure.

Clopidogrel prevented 21 more events per diabetic patients treated than did ASA. First, they provide information on the relative importance of blocking platelet activation mediated by thromboxane A 2yrial ADP, or by the combination of the 2 antagonists.

tria There were no major differences in terms of safety. Therefore, this population not only was at greater risk of an ischemic event but also was more responsive to clopidogrel, with an ARR of 6.

The NNT is the number of patients that must receive a particular intervention, for a specified length of time, to prevent 1 bad outcome, which is calculated by dividing the ARR into The ongoing Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance CHARISMA trial will capdie further define the effectiveness and cost-efficacy of dual antiplatelet therapy vs aspirin monotherapy in secondary prevention of coronary, cerebral, and peripheral arterial diseases, as well as in high-risk primary prevention.

Treatment periods ranged from 1 to 3 years. Clopidogrel, a new thienopyridine derivative similar to ticlopidine, is an inhibitor of platelet aggregation induced by adenosine diphosphate.

The overall safety profile of clopidogrel is at least as good as that of medium-dose aspirin. Copyright American Medical Association. Clopidogrel prevented 38 more events per diabetic capire receiving insulin than did ASA. They produce their antiplatelet effect through active metabolites that irreversibly modify the adenosine diphosphate ADP receptor the P2Y12 receptor on platelets, thereby inhibiting ADP-mediated platelet activation. In addition, patients with previous CABG, involvement of multiple vascular beds, history of more than 1 ischemic event, or diabetes had an apparent greater RRR with clopidogrel, suggesting that these subgroups may be more responsive to the beneficial effects of clopidogrel compared with the general study population.

Generate a file for use with external citation management software. Sign in to caprrie free article PDFs Sign in to access your subscriptions Sign in to your personal account.

The relative risk of life-threatening bleeding was 0. Gastrointestinal hemorrhages occurred in 1. Supplemental Content Full text links.

Four terms are used in this review to compare the efficacy of clopidogrel with ASA: Reported adverse experiences in the clopidogrel and aspirin groups judged to be severe included rash 0.

Sign in to access your subscriptions Sign in to your personal account. The recent CAPRIE trial clopidogrel versus aspirin in patients at risk of ischaemic events compared clopidogrel with aspirin in reducing the risk of vascular events in 19, patients with clinical manifestations of atherosclerosis.

The first antiplatelet agent to be evaluated, ASA is inexpensive, relatively safe, and widely used. Abstract The recent CAPRIE trial clopidogrel versus aspirin in patients at risk of ischaemic events compared clopidogrel with aspirin in reducing the risk of vascular events in 19, patients with clinical manifestations of atherosclerosis.

1 thoughts on “Caprie trial”

Leave a Reply

Your email address will not be published. Required fields are marked *